Abstract
Coronary artery diseases continue to be the most common causes of mortality and morbidity in the industrialized world, especially in the setting of acute myocardial infarction.
Anticoagulation during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) has traditionally been supported by anticoagulant unfractionated heparin (UFH). Recently, alternative anticoagulants such as low molecular weight heparin (LMWH) were included in the management of STEMI.
The aim of the present review is to compare efficacy and safety outcomes among patients receiving low molecular weight heparins (LMWH) or unfractionated heparin (UFH) while undergoing PCI for STEMI.
Keywords: STEMI, PCI, low-molecular weight heparins, unfractionated heparin, acute coronary syndromes, thrombosis, in – stent restenosis, bleeding, coronary intervention, adjuvant therapy.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Low - Molecular Weight Heparins and Unfractionated Heparins during Primary Coronary Intervention
Volume: 11 Issue: 2
Author(s): Chiara Cavallino, Matteo Santagostino, Emanuela Facchini, Virginia Di Ruocco and Andrea Rognoni
Affiliation:
Keywords: STEMI, PCI, low-molecular weight heparins, unfractionated heparin, acute coronary syndromes, thrombosis, in – stent restenosis, bleeding, coronary intervention, adjuvant therapy.
Abstract: Coronary artery diseases continue to be the most common causes of mortality and morbidity in the industrialized world, especially in the setting of acute myocardial infarction.
Anticoagulation during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) has traditionally been supported by anticoagulant unfractionated heparin (UFH). Recently, alternative anticoagulants such as low molecular weight heparin (LMWH) were included in the management of STEMI.
The aim of the present review is to compare efficacy and safety outcomes among patients receiving low molecular weight heparins (LMWH) or unfractionated heparin (UFH) while undergoing PCI for STEMI.
Export Options
About this article
Cite this article as:
Cavallino Chiara, Santagostino Matteo, Facchini Emanuela, Ruocco Virginia Di and Rognoni Andrea, Low - Molecular Weight Heparins and Unfractionated Heparins during Primary Coronary Intervention, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (2) . https://dx.doi.org/10.2174/1871525711311020004
DOI https://dx.doi.org/10.2174/1871525711311020004 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of COX-2 in Heart Pathology
Cardiovascular & Hematological Agents in Medicinal Chemistry The Therapeutic Potential of PhospholipaseA2 Inhibitors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Recent Advances in the Probe Development of Technetium-99m Molecular Imaging Agents
Current Organic Synthesis The Synthetic Cannabinoids Phenomenon
Current Pharmaceutical Design Blocking Leukocyte Rolling: Does it have a Role in Disease Prevention?
Vascular Disease Prevention (Discontinued) Anti-Atherosclerotic Therapy Based on Botanicals
Recent Patents on Cardiovascular Drug Discovery Gene Polymorphism of Angiotensin II Type 1 and Type 2 Receptors
Current Pharmaceutical Design Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology The Cardiovascular Nutrapharmacology of Resveratrol: Pharmacokinetics, Molecular Mechanisms and Therapeutic Potential
Current Medicinal Chemistry Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Anti-Cancer Agents in Medicinal Chemistry Innate Inflammatory Responses in Stroke: Mechanisms and Potential Therapeutic Targets
Current Medicinal Chemistry Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Emerging Roles for Vasoactive Peptides in Diagnostic and Therapeutic Strategies Against Atherosclerotic Cardiovascular Diseases
Current Protein & Peptide Science Effect of Flavonoids on Human Health: Old Subjects but New Challenges
Recent Patents on Biotechnology Melatonin as Antioxidant Under Pathological Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Optimal Medical Therapy for Coronary Artery Disease in 2011 – Perspectives from the STICH Trial
Cardiovascular & Hematological Agents in Medicinal Chemistry Genetics of Atherosclerosis in Murine Models
Current Drug Targets S1P Regulation of Macrophage Functions in the Context of Cancer
Anti-Cancer Agents in Medicinal Chemistry